Compare BioGaia AB with Similar Stocks
Dashboard
1
High Management Efficiency with a high ROE of 15.46%
2
Company has very low debt and has enough cash to service the debt requirements
3
With a growth in Net Profit of 49.93%, the company declared Very Positive results in Dec 25
4
With ROE of 24.82%, it has a very expensive valuation with a 9.30 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
SEK 11,590 Million (Small Cap)
37.00
NA
28.96%
-0.61
25.32%
8.82
Revenue and Profits:
Net Sales:
441 Million
(Quarterly Results - Dec 2025)
Net Profit:
99 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
96.47%
0%
96.47%
6 Months
159.19%
0%
159.19%
1 Year
185.44%
0%
185.44%
2 Years
192.5%
0%
192.5%
3 Years
205.48%
0%
205.48%
4 Years
286.14%
0%
286.14%
5 Years
275.45%
0%
275.45%
BioGaia AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
15.54%
EBIT Growth (5y)
13.08%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.70
Sales to Capital Employed (avg)
0.88
Tax Ratio
21.81%
Dividend Payout Ratio
121.60%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
77.27%
ROE (avg)
15.46%
Valuation key factors
Factor
Value
P/E Ratio
37
Industry P/E
Price to Book Value
9.30
EV to EBIT
27.20
EV to EBITDA
22.53
EV to Capital Employed
19.01
EV to Sales
7.03
PEG Ratio
NA
Dividend Yield
31.25%
ROCE (Latest)
69.88%
ROE (Latest)
24.82%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
440.60
326.60
34.91%
Operating Profit (PBDIT) excl Other Income
133.50
96.10
38.92%
Interest
0.20
3.60
-94.44%
Exceptional Items
0.00
0.00
Consolidate Net Profit
98.80
65.90
49.92%
Operating Profit Margin (Excl OI)
289.10%
275.40%
1.37%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 34.91% vs -19.30% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is 49.92% vs -25.03% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
1,538.20
1,422.70
8.12%
Operating Profit (PBDIT) excl Other Income
476.60
434.80
9.61%
Interest
8.40
1.40
500.00%
Exceptional Items
0.00
-13.40
100.00%
Consolidate Net Profit
332.80
351.40
-5.29%
Operating Profit Margin (Excl OI)
293.80%
287.60%
0.62%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 8.12% vs 9.73% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -5.29% vs -3.83% in Dec 2024
About BioGaia AB 
BioGaia AB
Pharmaceuticals & Biotechnology
Biogaia AB is a Sweden-based company engaged in the development and sell of probiotic products, primarily based on the Lactobacillus reuteri bacteria. The Company’s activities are divided into three segments: Finished consumer products, which distributes tablets, drops, Oral Rehydration Solutions (ORSs), and oral health products, among others; Component products, which is responsible for the sale of LifeTop Straw and Life Top Cap, as well as of cultures as an ingredient in licensee products, such as infant formula and dairy products; and Other products, including animal health goods. It collaborates with Nestle, Gerber, Delta Medical, InfectoPharmm, Ferring Middle East, AllergyCare, and Ewopharma, among others. Furthermore, the Company operates worldwide through a number of subsidiaries, such as Biogaia Biologics Inc, CapAble AB, TwoPac AB and Infant Bacterial Therapeutics AB.
Company Coordinates 
Company Details
Kungsbroplan 3 , STOCKHOLM None : 112 27
Registrar Details






